New research showed that tirzepatide, the compound in Zepbound, improved symptoms of obstructive sleep apnea.
Vous n'êtes pas connecté
A new drug trial is working to cure obstructive sleep apnoea in Australians.
New research showed that tirzepatide, the compound in Zepbound, improved symptoms of obstructive sleep apnea.
In recent research led by the University of California San Diego School of Medicine, scientists have found a new potential treatment for obstructive...
Eli Lilly (LLY) files for the approval of tirzepatide to treat obstructive sleep apnea in adults with obesity in the United States. If approved, sales...
Research raises possibility that tirzepatide could become first pharmaceutical treatment for the sleeping disorder
Researchers at University of California San Diego School of Medicine and international collaborators have led a worldwide, advanced study...
Blood tests offer a promising method to predict a person's risk of developing obstructive sleep apnea by measuring levels of specific biomarkers.
FRIDAY, June 21, 2024 -- A medication used to manage type 2 diabetes has been found effective in treating sleep apnea.The worldwide clinical trial...
WEDNESDAY, June 26, 2024 -- Tirzepatide reduces the apnea-hypopnea index (AHI) among individuals with moderate-to-severe obstructive sleep apnea and...
Eli Lilly on Friday said it applied for U.S. approval of its weight loss drug Zepbound for the treatment of the most common sleep-related breathing...
FRIDAY, June 28, 20204 (HealthDay news) -- An immunotherapy/chemotherapy combo drug can help early-stage breast cancer patients remain cancer-free...